Mesenchymal stromal cells as vehicles of tetravalent bispecific Tandab (CD3/CD19) for the treatment of B cell lymphoma combined with IDO pathway inhibitor d-1-methyl-tryptophan

BACKGROUND: Although blinatumomab, a bispecific T cell engaging antibody, exhibits high clinical response rates in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin’s lymphoma (B-NHL), it still has some limitations because of its short half-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiaolong, Yang, Yuanyuan, Zhang, Leisheng, Lu, Yang, Zhang, Qing, Fan, Dongmei, Zhang, Yizhi, Zhang, Yanjun, Ye, Zhou, Xiong, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322661/
https://www.ncbi.nlm.nih.gov/pubmed/28228105
http://dx.doi.org/10.1186/s13045-017-0397-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322661/
https://www.ncbi.nlm.nih.gov/pubmed/28228105
http://dx.doi.org/10.1186/s13045-017-0397-z

Ejemplares similares